intranasal

Fluticasone furoate (Avamys) 是一种合成的三氟化皮质类固醇，衍生自氟替卡松，Kd 为 0.3 nM。Fluticasone furoate 具有有效的抗炎、抗哮喘活性和低全身暴露。Fluticasone furoate 可用作过敏性鼻炎治疗研究的鼻喷雾剂。

Vazegepant hydrochloride (Vazegepant HCl) 是一种用于偏头痛的鼻用 gepant，是一种高度亲和性CGRP 受体拮抗剂 (hCGRPKi=0.023 nM)。它可能有助于有效管理 COVID-19 相关肺部炎症。

Etripamil (MSP-2017) 是一种短效L 型钙通道拮抗剂，可用于治疗阵发性室上性心动过速的研究。它通过抑制房室结细胞中钙慢通道的钙离子流入，显示房室结传导并延长房室结不应期

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

Fpl 14294 is a novel CCK-8 agonist with effective intranasal anorectic activity in the rat.

Dexamethasone cipecilate is a long-acting intranasal corticosteroid and a highly lipophilic anti-inflammatory corticosteroid.

Cyclic di-IMP (sodium salt) (c-di-IMP) is a synthetic second messenger structurally related to the bacterial second messengers cyclic di-GMP and cyclic di-AMP . C-di-IMP has adjuvant properties when co-administered with antigens in vitro and by mucosal routes in vivo. C-di-IMP enriches the population of MHC class I and II, CD80, CD86, CD40, and CD54 positive dendritic cells derived from murine bone marrow. It also stimulates macrophages at 500 ng/ml. Mice immunized with β-galactosidase (β-gal) plus c-di-IMP through the intranasal route show a humoral immune response, evidenced by an increase in IgG titers up to 2-fold compared to mice immunized with β-gal alone. Mice immunized with β-gal plus c-di-IMP also exhibit a Th1/Th2 response, indicating that the adjuvant activity of c-di-IMP leads to a cellular immune response as well.

Zanamivir-13C,15N2is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza. 1.Elliott, M.Zanamivir: From drug design to the clinicPhilos. Trans. R. Soc. Lond. B Biol Sci.356(1416)1885-1893(2001)